Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc. is a U.S.-based clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders. Its lead program is BNC210, an oral selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor being studied for social anxiety disorder and post-traumatic stress disorder, alongside earlier-stage CNS programs and partnered assets.

−3,0 %

−2,4 %

3.56

3.56

— Neuphoria Therapeutics Inc.
%
Clinical-stage drug candidates70% BNC210 and other internal programs in discovery, preclinical, and clinical development.
Collaborative CNS research20% Partnered programs with Merck targeting cognitive deficits in Alzheimer’s disease and other CNS conditions.
Licensing and milestone income10% License revenue, milestone payments, and potential royalties from out-licensed intellectual property.

Neuphoria does not sell commercial medicines today; its direct counterparties are pharmaceutical partners, licensees,...

  • Pharmaceutical collaboration partnersprimary

    Companies such as Merck that co-develop or license CNS programs and may fund development milestones.

  • Licensees of out-licensed IPsecondary

    Third parties developing licensed assets that can generate milestone and royalty income.

  • Future physicians and patientsprimary

    Psychiatrists, neurologists, and patients who would use approved BNC210-based therapies if commercialized.

  • Clinical trial participantssecondary

    Patients enrolled in SAD and PTSD studies who generate the clinical evidence base for the pipeline.

Neuphoria is headquartered in the United States and is now listed on Nasdaq in the U.S...

  • •Headquartered in the United States
  • •Listed on Nasdaq under the symbol NEUP
  • •Clinical and regulatory exposure spans U.S. and foreign markets
  • •Historical corporate roots in Australia through Bionomics
  • •Partner and license economics can be country-by-country

Neuphoria’s strategy centers on advancing BNC210 through clinical development for SAD and PTSD while preserving...

01
Advance BNC210 clinical programsshort-term

Clinical proof-of-concept is the main path to value creation for the company.

02
Leverage partnering for CNS assetsmedium-term

Collaborations can provide external validation and non-dilutive economics.

03
Preserve optionality through strategic alternativesshort-term

The company is exploring paths that could maximize value beyond stand-alone development.

Neuphoria is a clinical-stage biopharmaceutical company with no approved products, so its value depends on successful...

critical

Clinical failure of BNC210 or other pipeline assets

The company’s lead value driver is still in development and may not show efficacy or safety in later trials.

Scope
BNC210, SAD Prevail, PSTD ATTUNE
Materiality
high
high

Regulatory approval risk

Even successful trials must satisfy FDA and other regulators, which can impose additional studies or restrictions.

Scope
U.S. and foreign drug approvals
Materiality
high
high

Competition in anxiety and PTSD therapies

Existing generics and emerging CNS programs may reach patients sooner or with better efficacy.

Scope
PTSD, SAD, CNS therapeutics
Materiality
high
high

Capital and dilution risk

Clinical-stage biotechs often require external funding before any product revenue exists.

Scope
Operating runway and development funding
Materiality
high
medium

Commercialization and partner dependence

If products are approved, the company may need third parties for sales, marketing, and distribution.

Scope
Future product launch
Materiality
medium
License and milestone revenue recognition
Can create large swings in reported revenue between periods
Fair value of warrant liabilities
Can materially change net loss without affecting cash
R&D incentive awards
Affects reported R&D spend and operating loss
Restructuring and right-of-use asset impairment
Can increase operating expenses and reduce comparability

Neumora Therapeutics, Inc.

NMRA · Biological Products, (No Diagnostic Substances)

MapLight Therapeutics, Inc.

MPLT · Pharmaceutical Preparations

Pasithea Therapeutics Corp.

KTTAW · Pharmaceutical Preparations

Enveric Biosciences, Inc.

ENVB · Pharmaceutical Preparations

Protagenic Therapeutics, Inc.\new

PTIX · Pharmaceutical Preparations

Cyclerion Therapeutics, Inc.

CYCN · Pharmaceutical Preparations

: 29/04/2026